Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie deruxtecan Patritumab plus pembrolizumab z innymi środkami przeciwnowotworowymi u uczestników z wczesnym stadium trójwetnego raka piersi o wysokim ryzyku lub hormonalnym raku piersi-nogim (MK-1022-010, Herthena-Breast-03)

11 listopada 2026 zaktualizowane przez: Merck Sharp & Dohme LLC

Randomizowane badanie fazy 2 w otwartym hacie w celu oceny bezpieczeństwa i skuteczności deruxtecan patritumab plus pembrolizumab podawane przed lub po karboplatynie/paklitakselu plus pembrolizumab w porównaniu z pembrolizumabem w połączeniu z chemioterapią, a następnie chirurgia i uzupełnienie pembrolizumabu pembrolizumab Negatywny lub hormonalny receptor-niski pozytywny/ludzki czynnik naskórkowy receptor receptor-2 ujemny rak piersi (Herthena-Breast03)

Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn:

  • About the safety of the study treatments and if people tolerate them
  • If people who receive patritumab deruxtecan, pembrolizumab, and chemotherapy before surgery have fewer cancer cells removed during surgery compared to those who receive only pembrolizumab (pembro) and chemotherapy.

Przegląd badań

Typ studiów

Interwencyjne

Zapisy (Szacowany)

372

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

      • Córdoba, Hiszpania, 14004
        • Rekrutacyjny
        • Hospital Universitario Reina Sofia ( Site 1702)
        • Kontakt:
          • Study Coordinator
          • Numer telefonu: +34 957012408
    • Catalonia
      • Badalona, Catalonia, Hiszpania, 08916
        • Rekrutacyjny
        • Institut Català d'Oncologia (ICO) - Badalona ( Site 1700)
        • Kontakt:
          • Study Coordinator
          • Numer telefonu: +34934978925
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Hiszpania, 28027
        • Rekrutacyjny
        • Clinica Universidad de Navarra ( Site 1703)
        • Kontakt:
          • Study Coordinator
          • Numer telefonu: +34913531920
      • Seoul, Korea Południowa, 03080
        • Rekrutacyjny
        • Seoul National University Hospital ( Site 2400)
        • Kontakt:
          • Study Coordinator
          • Numer telefonu: +82220720850
      • Seoul, Korea Południowa, 05505
        • Rekrutacyjny
        • Asan Medical Center ( Site 2401)
        • Kontakt:
          • Study Coordinator
          • Numer telefonu: +82230103217
      • Seoul, Korea Południowa, 03722
        • Rekrutacyjny
        • Severance Hospital, Yonsei University Health System ( Site 2402)
        • Kontakt:
          • Study Coordinator
          • Numer telefonu: +82222288135
    • California
      • Santa Monica, California, Stany Zjednoczone, 90404
        • Rekrutacyjny
        • UCLA Hematology/Oncology - Parkside ( Site 0021)
        • Kontakt:
          • Study Coordinator
          • Numer telefonu: 424-402-9520
    • Illinois
      • Skokie, Illinois, Stany Zjednoczone, 60077
        • Rekrutacyjny
        • Orchard Healthcare Research Inc. ( Site 0006)
        • Kontakt:
          • Study Coordinator
          • Numer telefonu: 847-568-9932
    • Montana
      • Billings, Montana, Stany Zjednoczone, 59102
        • Rekrutacyjny
        • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003)
        • Kontakt:
          • Study Coordinator
          • Numer telefonu: 406-238-6685
    • Oregon
      • Happy Valley, Oregon, Stany Zjednoczone, 97015
        • Rekrutacyjny
        • Northwest Cancer Specialists, P.C. ( Site 8003)
        • Kontakt:
          • Study Coordinator
          • Numer telefonu: 360-944-9889
    • Tennessee
      • Nashville, Tennessee, Stany Zjednoczone, 37203
        • Rekrutacyjny
        • SCRI Oncology Partners ( Site 7000)
        • Kontakt:
          • Study Coordinator
          • Numer telefonu: 844-482-4812
    • Texas
      • Dallas, Texas, Stany Zjednoczone, 75246
        • Rekrutacyjny
        • Texas Oncology - DFW ( Site 8000)
        • Kontakt:
          • Study Coordinator
          • Numer telefonu: 214-370-1067
      • Houston, Texas, Stany Zjednoczone, 77030
        • Rekrutacyjny
        • Houston Methodist Hospital ( Site 0022)
        • Kontakt:
          • Study Coordinator
          • Numer telefonu: 713-441-9948
    • Virginia
      • Norfolk, Virginia, Stany Zjednoczone, 23502
        • Rekrutacyjny
        • Virginia Oncology Associates (VOA) ( Site 8001)
        • Kontakt:
          • Study Coordinator
          • Numer telefonu: 844-482-4812
      • Taichung, Tajwan, 407
        • Rekrutacyjny
        • Taichung Veterans General Hospital ( Site 2502)
        • Kontakt:
          • Study Coordinator
          • Numer telefonu: +886423592525
      • Tainan, Tajwan, 704
        • Rekrutacyjny
        • National Cheng Kung University Hospital ( Site 2503)
        • Kontakt:
          • Study Coordinator
          • Numer telefonu: +88662353535
      • Taipei, Tajwan, 112
        • Rekrutacyjny
        • Koo Foundation Sun Yat-Sen Cancer Center ( Site 2501)
        • Kontakt:
          • Study Coordinator
          • Numer telefonu: 886228970011x1686

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has locally advanced, non-metastatic (M0), breast cancer, defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per current American Joint Committee on Cancer (AJCC) criteria: cT1c, N1-N2; cT2, N0-N2; cT3, N0-N2; or cT4a-d, N0-N2
  • Has centrally confirmed diagnosis of breast cancer that is triple-negative or HR-low+/HER2- breast cancer that will be treated according to the triple-negative breast cancer (TNBC) paradigm
  • Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
  • Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 28 days prior to allocation/randomization
  • Has left ventricular ejection fraction (LVEF) of ≥50% or ≥ lower limit of normal (LLN) as assessed by echocardiogram (ECHO) or multigate acquisition scan (MUGA) scan

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has uncontrolled or significant cardiovascular disease before randomization
  • Has any history of or evidence of any current leptomeningeal carcinomatosis.
  • Has clinically significant corneal disease
  • Has human immunodeficiency virus (HIV) infection with a history of Kaposi sarcoma and/or multicentric Castleman disease
  • Has evidence of ongoing, uncontrolled, systemic bacterial, fungal, or viral infection
  • Has received prior therapy with an anti-programmed death (PD)-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor
  • Has received any prior treatment, including radiation, systemic therapy, and/or definitive surgery for currently diagnosed breast cancer
  • Has received prior treatment with an anti-human epidermal growth factor receptor 3 (HER3) antibody and/or antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., trastuzumab deruxtecan)
  • Has metastatic (Stage IV) breast cancer or cN3 nodal involvement
  • Has known additional malignancy that is progressing or has required active treatment within the past 5 years
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current or suspected ILD
  • Has an active infection requiring systemic therapy
  • Has concurrent active HBV and HCV infection
  • Has clinically severe respiratory compromise resulting from intercurrent pulmonary illness

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Part 1, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin

In Part 1, participants receive neoadjuvant pembrolizumab 200 mg via intravenous (IV) infusion every 3 weeks (Q3W) plus patritumab deruxtecan via IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg via IV infusion Q3W plus paclitaxel 80 mg/m^2 via IV infusion every week (QW) and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer.

Administered via IV infusion as neoadjuvant treatment

Inne nazwy:
  • U3-1402
  • HER3-DXd
  • MK-1022

Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

Inne nazwy:
  • MK-3475
  • KEYTRUDA®

Administered via IV infusion as neoadjuvant treatment

Inne nazwy:
  • TAXOL®
  • ONXAL®

Administered via IV infusion as neoadjuvant treatment

Inne nazwy:
  • PARAPLATYNA®
Eksperymentalny: Part 2, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin

In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion every Q3W plus patritumab deruxtecan (dose to be determined in part 1) IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks. At 3-6 weeks after last dose of neoadjuvant treatment, participants undergo surgery for breast cancer. After surgery, participants receive adjuvant pembrolizumab 400 mg IV every 6 weeks (Q6W) for ~30 weeks. Additional adjuvant treatment of physician's choice (TPC) may be given to participants with residual disease. TPC options are olaparib 300 mg oral twice daily (BID) for 1 year (participants with germline BRCA mutation [gBRCAm] only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV Q3W or every 2 weeks (Q2W) and cyclophosphamide 600 mg/m^2 IV Q3W or Q2W for 4 doses.

Administered via IV infusion as neoadjuvant treatment

Inne nazwy:
  • U3-1402
  • HER3-DXd
  • MK-1022

Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

Inne nazwy:
  • MK-3475
  • KEYTRUDA®

Administered via IV infusion as neoadjuvant treatment

Inne nazwy:
  • TAXOL®
  • ONXAL®

Administered via IV infusion as neoadjuvant treatment

Inne nazwy:
  • PARAPLATYNA®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Inne nazwy:
  • ADRIAMYCYNA®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Inne nazwy:
  • ELLENCE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Inne nazwy:
  • CYTOXAN®

Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2

Inne nazwy:
  • XELODA®

Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2

Inne nazwy:
  • LYNPARZA®
Eksperymentalny: Part 2, B: Pembrolizumab + paclitaxel + carboplatin → Pembrolizumab + patritumab deruxtecan

In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus patritumab deruxtecan (dose to be determined in part 1) via IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for ~30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W or Q2W and cyclophosphamide 600 mg/m^2 IV infusion Q3W or Q2W for 4 doses.

Administered via IV infusion as neoadjuvant treatment

Inne nazwy:
  • U3-1402
  • HER3-DXd
  • MK-1022

Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

Inne nazwy:
  • MK-3475
  • KEYTRUDA®

Administered via IV infusion as neoadjuvant treatment

Inne nazwy:
  • TAXOL®
  • ONXAL®

Administered via IV infusion as neoadjuvant treatment

Inne nazwy:
  • PARAPLATYNA®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Inne nazwy:
  • ADRIAMYCYNA®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Inne nazwy:
  • ELLENCE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Inne nazwy:
  • CYTOXAN®

Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2

Inne nazwy:
  • XELODA®

Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2

Inne nazwy:
  • LYNPARZA®
Aktywny komparator: Part 2, C: Pembro + paclitaxel + carboplatin→ Pembro + doxorubicin (or epirubicin) +cyclophosphamide

In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W and cyclophosphamide 600 mg/m^2 IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for approximately 30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only) or capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles.

Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

Inne nazwy:
  • MK-3475
  • KEYTRUDA®

Administered via IV infusion as neoadjuvant treatment

Inne nazwy:
  • TAXOL®
  • ONXAL®

Administered via IV infusion as neoadjuvant treatment

Inne nazwy:
  • PARAPLATYNA®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Inne nazwy:
  • ADRIAMYCYNA®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Inne nazwy:
  • ELLENCE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Inne nazwy:
  • CYTOXAN®

Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2

Inne nazwy:
  • XELODA®

Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2

Inne nazwy:
  • LYNPARZA®

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Part 1: Number of Participants Experiencing an Adverse Event (AE)
Ramy czasowe: Up to ~43 weeks

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 1.

Up to ~43 weeks
Part 1: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)
Ramy czasowe: Up to 21 days

A DLT is defined by the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) Version 5.0, assessed by investigator as drug-related: Grade (gr) 3 or 4 nonhematologic toxicity (with exceptions); gr 3 or gr 4 laboratory values (with exceptions); gr 3 or 4 febrile neutropenia; prolonged delay (>2 weeks) in initiating Cycle 2 (cycle length = 3 weeks) due to intervention-related toxicity; any intervention-related toxicity that causes the participant to discontinue intervention during Cycle 1; interstitial lung disease as per investigator; any other gr ≥3 pulmonary toxicity; or gr 5 toxicity.

Up to 21 days
Part 1: Number of Participants who Discontinued Study Treatment Due to an AE
Ramy czasowe: Up to ~30 weeks

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 1.

Up to ~30 weeks
Part 2: Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0
Ramy czasowe: Up to ~30 weeks

pCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery.

Up to ~30 weeks
Part 2: Number of Participants Experiencing an AE
Ramy czasowe: Up to ~103 weeks

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 2.

Up to ~103 weeks
Part 2: Number of Participants who Discontinued Study Treatment Due to an AE
Ramy czasowe: Up to ~90 weeks

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 2.

Up to ~90 weeks

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Part 2: pCR-No Ductal Carcinoma in Situ (DCIS) Rate Using the Definition of ypT0 ypN0
Ramy czasowe: Up to ~30 weeks

pCR-no DCIS (ypT0 ypN0) is defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery.

Up to ~30 weeks
Part 2: Event-Free Survival (EFS)
Ramy czasowe: Up to ~100 months

EFS is defined as the time from randomization to disease progression that precludes surgery, local or distant recurrence, or death due to any cause, whichever occurs first.

Up to ~100 months
Part 2: Overall Survival (OS)
Ramy czasowe: Up to ~100 months

OS is defined as the time from randomization to date of death due to any cause.

Up to ~100 months
Part 2: Distant Progression or Distant Recurrence-Free Survival (DPDRFS)
Ramy czasowe: Up to ~100 months

DPDRFS is defined as the time from randomization to first distant progression or distant recurrence event as assessed or death due to any cause, whichever occurs first.

Up to ~100 months
Part 2: Residual Cancer Burden (RCB)
Ramy czasowe: Up to ~30 weeks

RCB is defined as residual disease in either the breast or lymph node at the time of surgery. RCB score provides a continuous measurement of the extent of residual cancer. There are four RCB classes: RCB-0 (RCB score 0), RCB-1 (0< RCB score <1.36), RCB-2 (1.36 <RCB score <3.28), and RCB-3 (RCB score >3.28).

Up to ~30 weeks

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Współpracownicy

Śledczy

  • Dyrektor Studium: Medical Director, Merck Sharp & Dohme LLC

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

20 marca 2025

Zakończenie podstawowe (Szacowany)

31 grudnia 2029

Ukończenie studiów (Szacowany)

16 marca 2031

Daty rejestracji na studia

Pierwszy przesłany

21 stycznia 2025

Pierwszy przesłany, który spełnia kryteria kontroli jakości

21 stycznia 2025

Pierwszy wysłany (Rzeczywisty)

28 stycznia 2025

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

12 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

11 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj